Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifedipine GITS + candesartan cilexetil fixed-dose combination versus nifedipine GITS monotherapy in inadequately controlled essential hypertension
2012-004857-10Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nifedipine and candesartan cilexetil in essential hypertension (3 arms), sponsored by Bayer. Primary endpoint: Change from baseline in mean seated systolic blood pressure. Started Jun 2013; status: completed.
02
Drugs
nifedipinecandesartan cilexetil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2012-004857-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004857-10.